Safrazine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Safrazine
Accession Number
DB09253
Type
Small Molecule
Groups
Withdrawn
Description

Safrazine (Safra) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was introduced as an antidepressant in the 1960s, but has since been discontinued.

Structure
Thumb
Synonyms
  • Safra
Categories
UNII
F5G0P5378C
CAS number
33419-68-0
Weight
Average: 208.261
Monoisotopic: 208.121177763
Chemical Formula
C11H16N2O2
InChI Key
IBWPUTAKVGZXRB-UHFFFAOYSA-N
InChI
InChI=1S/C11H16N2O2/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10/h4-6,8,13H,2-3,7,12H2,1H3
IUPAC Name
[4-(2H-1,3-benzodioxol-5-yl)butan-2-yl]hydrazine
SMILES
CC(CCC1=CC2=C(OCO2)C=C1)NN

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineSafrazine may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineSafrazine may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineSafrazine may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Safrazine.Experimental
AcarboseSafrazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololSafrazine may increase the hypotensive activities of Acebutolol.Approved
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Safrazine.Experimental
AlbiglutideSafrazine may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Safrazine.Approved, Illicit
AliskirenSafrazine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Safrazine.Approved, Investigational
AlogliptinSafrazine may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Safrazine.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Safrazine.Illicit
AlprenololSafrazine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Safrazine.Approved
AmbrisentanSafrazine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineSafrazine may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineSafrazine may increase the serotonergic activities of Amitriptyline.Approved
AmlodipineSafrazine may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Safrazine is combined with Amoxapine.Approved
AmphetamineSafrazine may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Safrazine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Safrazine is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Safrazine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Arformoterol.Approved, Investigational
AtenololSafrazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineSafrazine may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineSafrazine may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Bambuterol.Approved
BenazeprilSafrazine may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideSafrazine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypertensive activities of Safrazine.Withdrawn
BenzphetamineSafrazine may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilSafrazine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Safrazine.Approved
BetaxololSafrazine may increase the hypotensive activities of Betaxolol.Approved
BethanidineSafrazine may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Safrazine is combined with Bezafibrate.Approved
BietaserpineSafrazine may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostSafrazine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololSafrazine may increase the hypotensive activities of Bisoprolol.Approved
BosentanSafrazine may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Safrazine may increase the hypotensive activities of BQ-123.Investigational
BretyliumSafrazine may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Safrazine is combined with Brimonidine.Approved
BrofaromineBrofaromine may increase the hypertensive activities of Safrazine.Experimental
BromocriptineSafrazine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololSafrazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Safrazine.Approved, Illicit, Investigational, Vet Approved
BupropionSafrazine may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Safrazine.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Safrazine.Approved, Illicit, Vet Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Safrazine.Approved
CadralazineSafrazine may increase the hypotensive activities of Cadralazine.Experimental
CafedrineSafrazine may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinSafrazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanSafrazine may increase the hypotensive activities of Candesartan.Approved
CandoxatrilSafrazine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilSafrazine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Safrazine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Safrazine.Illicit, Vet Approved
CaroxazoneSafrazine may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololSafrazine may increase the hypotensive activities of Carteolol.Approved
CarvedilolSafrazine may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololSafrazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideSafrazine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineSafrazine may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideSafrazine may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneSafrazine may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineSafrazine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilSafrazine may increase the hypotensive activities of Cilazapril.Approved
CirazolineSafrazine may increase the hypertensive activities of Cirazoline.Experimental
CitalopramSafrazine may increase the serotonergic activities of Citalopram.Approved
ClemastineSafrazine may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineSafrazine may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidineSafrazine may increase the hypotensive activities of Clonidine.Approved
CloranololSafrazine may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Safrazine.Approved, Illicit
CryptenamineSafrazine may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Safrazine.Approved
CyclopenthiazideSafrazine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideSafrazine may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineSafrazine may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinSafrazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineSafrazine may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinSafrazine may increase the hypotensive activities of Debrisoquin.Approved
DelaprilSafrazine may increase the hypotensive activities of Delapril.Experimental
DeserpidineSafrazine may increase the hypotensive activities of Deserpidine.Approved
DesipramineSafrazine may increase the serotonergic activities of Desipramine.Approved
DesvenlafaxineSafrazine may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidateSafrazine may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetamineSafrazine may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanSafrazine may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Safrazine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Safrazine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Safrazine.Approved
DiazoxideSafrazine may increase the hypotensive activities of Diazoxide.Approved
DibenzepinSafrazine may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorspermineSafrazine may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionSafrazine may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineSafrazine may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Safrazine.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Safrazine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Safrazine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Safrazine.Experimental, Illicit
DiltiazemSafrazine may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Safrazine.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Safrazine is combined with Dipivefrin.Approved
DisopyramideSafrazine may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Safrazine is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideSafrazine may increase the hypotensive activities of Dorzolamide.Approved
DosulepinSafrazine may increase the serotonergic activities of Dosulepin.Approved
DoxapramSafrazine may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinSafrazine may increase the hypotensive activities of Doxazosin.Approved
DoxepinSafrazine may increase the serotonergic activities of Doxepin.Approved
DoxylamineSafrazine may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Safrazine.Investigational
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Safrazine.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Safrazine is combined with Droxidopa.Approved, Investigational
DulaglutideSafrazine may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineSafrazine may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Safrazine.Experimental, Illicit
EfonidipineSafrazine may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Safrazine.Approved, Investigational
EmpagliflozinSafrazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilSafrazine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatSafrazine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineSafrazine may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Safrazine.Approved, Investigational
EpanololSafrazine may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Safrazine is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolSafrazine may increase the hypotensive activities of Epoprostenol.Approved
EprosartanSafrazine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineSafrazine may increase the hypertensive activities of Ergotamine.Approved
EscitalopramSafrazine may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapineSafrazine may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Safrazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Safrazine.Approved, Illicit
EtoperidoneSafrazine may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Safrazine.Illicit, Vet Approved
ExenatideSafrazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineSafrazine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Safrazine is combined with Fenfluramine.Illicit, Withdrawn
FenoldopamSafrazine may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Fenoterol.Approved
FentanylFentanyl may increase the serotonergic activities of Safrazine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidSafrazine may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetineSafrazine may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineSafrazine may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Formoterol.Approved, Investigational
FosinoprilSafrazine may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Safrazine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypertensive activities of Safrazine.Approved, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Safrazine.Experimental
GliclazideSafrazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideSafrazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSafrazine may increase the hypoglycemic activities of Glipizide.Approved
GlyburideSafrazine may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzSafrazine may increase the hypotensive activities of Guanabenz.Approved
GuanadrelSafrazine may increase the hypotensive activities of Guanadrel.Approved
GuanazodineSafrazine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineSafrazine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineSafrazine may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorSafrazine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzSafrazine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanSafrazine may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypertensive activities of Safrazine.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Safrazine.Approved, Illicit
HexamethoniumSafrazine may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazineHydracarbazine may increase the hypertensive activities of Safrazine.Experimental
HydralazineSafrazine may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideSafrazine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideSafrazine may increase the hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineSafrazine may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilSafrazine may increase the hypotensive activities of Imidapril.Investigational
ImipramineSafrazine may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Indacaterol.Approved
IndalpineSafrazine may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideSafrazine may increase the hypotensive activities of Indapamide.Approved
IndenololSafrazine may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminSafrazine may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartSafrazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSafrazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSafrazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSafrazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSafrazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSafrazine may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Safrazine.Approved
IprindoleSafrazine may increase the serotonergic activities of Iprindole.Experimental
IproclozideIproclozide may increase the hypertensive activities of Safrazine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Safrazine.Withdrawn
IrbesartanSafrazine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Safrazine.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Safrazine is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Safrazine is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Isoprenaline.Approved
IsradipineSafrazine may increase the hypotensive activities of Isradipine.Approved
KetanserinSafrazine may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Safrazine.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Safrazine.Approved, Nutraceutical, Withdrawn
LabetalolSafrazine may increase the hypotensive activities of Labetalol.Approved
LacidipineSafrazine may increase the hypotensive activities of Lacidipine.Approved
LatanoprostSafrazine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineSafrazine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Safrazine.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Safrazine.Approved
LevomilnacipranSafrazine may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinSafrazine may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Safrazine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Safrazine is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Safrazine is combined with Linezolid.Approved, Investigational
LinsidomineSafrazine may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideSafrazine may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineSafrazine may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilSafrazine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Safrazine.Approved
LithiumThe risk or severity of adverse effects can be increased when Safrazine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Safrazine.Illicit
LofepramineSafrazine may increase the serotonergic activities of Lofepramine.Experimental
LofexidineSafrazine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanSafrazine may increase the hypotensive activities of Losartan.Approved
MacitentanSafrazine may increase the hypotensive activities of Macitentan.Approved
ManidipineSafrazine may increase the hypotensive activities of Manidipine.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Safrazine.Approved
MebanazineMebanazine may increase the hypertensive activities of Safrazine.Withdrawn
MecamylamineSafrazine may increase the hypotensive activities of Mecamylamine.Approved
MecaserminSafrazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedroneSafrazine may increase the hypertensive activities of Mephedrone.Investigational
MephentermineSafrazine may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Safrazine.Experimental
MequitazineSafrazine may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolSafrazine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminSafrazine may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Safrazine.Approved, Illicit
MethamphetamineSafrazine may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineSafrazine may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineSafrazine may increase the hypertensive activities of Methoxamine.Approved
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Safrazine.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Safrazine is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Safrazine.Experimental
Methylene blueSafrazine may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateSafrazine may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetipranololSafrazine may increase the hypotensive activities of Metipranolol.Approved
MetolazoneSafrazine may increase the hypotensive activities of Metolazone.Approved
MetoprololSafrazine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineSafrazine may increase the hypotensive activities of Metyrosine.Approved
MianserinSafrazine may increase the neurotoxic activities of Mianserin.Approved
MibefradilSafrazine may increase the hypotensive activities of Mibefradil.Withdrawn
MidodrineSafrazine may increase the hypertensive activities of Midodrine.Approved
MidomafetamineSafrazine may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
MifepristoneSafrazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolSafrazine may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranSafrazine may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Safrazine.Approved
MinoxidilSafrazine may increase the hypotensive activities of Minoxidil.Approved
MirtazapineSafrazine may increase the central neurotoxic activities of Mirtazapine.Approved
MMDASafrazine may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Safrazine is combined with Moclobemide.Approved
MoexiprilSafrazine may increase the hypotensive activities of Moexipril.Approved
MoxonidineSafrazine may increase the hypotensive activities of Moxonidine.Approved
MuzolimineSafrazine may increase the hypotensive activities of Muzolimine.Experimental
NadololSafrazine may increase the hypotensive activities of Nadolol.Approved
NaftopidilSafrazine may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Safrazine.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Safrazine.Approved, Investigational
NateglinideSafrazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololSafrazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneSafrazine may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Safrazine.Withdrawn
NicardipineSafrazine may increase the hypotensive activities of Nicardipine.Approved
NicorandilSafrazine may increase the hypotensive activities of Nicorandil.Approved
NiguldipineSafrazine may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineSafrazine may increase the hypotensive activities of Nilvadipine.Approved
NimodipineSafrazine may increase the hypotensive activities of Nimodipine.Approved
NisoldipineSafrazine may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineSafrazine may increase the hypotensive activities of Nitrendipine.Approved
NitroprussideSafrazine may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrineSafrazine may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Safrazine.Approved, Illicit
NortriptylineSafrazine may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Safrazine.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Safrazine is combined with Olanzapine.Approved, Investigational
OlmesartanSafrazine may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Olodaterol.Approved
OmapatrilatSafrazine may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolSafrazine may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Safrazine.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Orciprenaline.Approved
OxprenololSafrazine may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Safrazine.Approved, Investigational, Vet Approved
PargylineSafrazine may increase the hypotensive activities of Pargyline.Approved
ParoxetineSafrazine may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololSafrazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineSafrazine may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Safrazine.Approved, Vet Approved
PentoliniumSafrazine may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Safrazine.Approved, Vet Approved, Withdrawn
PerindoprilSafrazine may increase the hypotensive activities of Perindopril.Approved
PethidineSafrazine may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Safrazine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Safrazine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Safrazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Safrazine.Experimental
PhenoxybenzamineSafrazine may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Safrazine.Withdrawn
PhentermineSafrazine may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineSafrazine may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineSafrazine may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Safrazine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Safrazine.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Safrazine.Investigational
PinacidilSafrazine may increase the hypotensive activities of Pinacidil.Withdrawn
PindololSafrazine may increase the hypotensive activities of Pindolol.Approved
PioglitazoneSafrazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Safrazine.Investigational
PirlindolePirlindole may increase the hypertensive activities of Safrazine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Safrazine.Withdrawn
PizotifenSafrazine may increase the anticholinergic activities of Pizotifen.Approved
PolythiazideSafrazine may increase the hypotensive activities of Polythiazide.Approved
PramlintideSafrazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinSafrazine may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Procaterol.Approved
PropranololSafrazine may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineSafrazine may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Safrazine.Investigational
PseudoephedrineSafrazine may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilSafrazine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineSafrazine may increase the hypoglycemic activities of Quinine.Approved
RamiprilSafrazine may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Safrazine.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Safrazine.Approved
RemikirenSafrazine may increase the hypotensive activities of Remikiren.Approved
RepaglinideSafrazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineSafrazine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Safrazine is combined with Reserpine.Approved
RilmenidineSafrazine may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatSafrazine may increase the hypotensive activities of Riociguat.Approved
RitobegronSafrazine may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Safrazine is combined with Ritodrine.Approved
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Safrazine.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Safrazine.Approved, Investigational
RosiglitazoneSafrazine may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Safrazine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Salmeterol.Approved
SaprisartanSafrazine may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinSafrazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Safrazine.Approved, Investigational, Vet Approved
SelexipagSafrazine may increase the hypotensive activities of Selexipag.Approved
SertralineSafrazine may increase the serotonergic activities of Sertraline.Approved
SitagliptinSafrazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanSafrazine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilSafrazine may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Safrazine.Approved, Investigational
SulfadiazineSafrazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSafrazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleSafrazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Safrazine.Approved, Investigational
SunitinibSafrazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololSafrazine may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Safrazine.Approved
TelmisartanSafrazine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilSafrazine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Safrazine is combined with Terbutaline.Approved
TerlipressinSafrazine may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Safrazine.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Safrazine.Approved
TetrahydropalmatineSafrazine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineSafrazine may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineSafrazine may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Safrazine.Approved
TiboloneSafrazine may increase the hypotensive activities of Tibolone.Approved
TicrynafenSafrazine may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Safrazine.Experimental
TimololSafrazine may increase the hypotensive activities of Timolol.Approved
TolazamideSafrazine may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineSafrazine may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideSafrazine may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Safrazine.Approved, Withdrawn
TolonidineSafrazine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Safrazine.Approved
TorasemideSafrazine may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Safrazine.Approved, Investigational
TrandolaprilSafrazine may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Safrazine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Safrazine.Approved
TravoprostSafrazine may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Safrazine is combined with Trazodone.Approved, Investigational
TreprostinilSafrazine may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideSafrazine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinSafrazine may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanSafrazine may increase the hypotensive activities of Trimethaphan.Approved
TrimipramineSafrazine may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneSafrazine may increase the hypotensive activities of Unoprostone.Approved
UrapidilSafrazine may increase the hypotensive activities of Urapidil.Investigational
ValsartanSafrazine may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxineSafrazine may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Safrazine is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Safrazine.Approved
VincamineSafrazine may increase the hypotensive activities of Vincamine.Experimental
VinpocetineSafrazine may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Safrazine.Approved
XipamideSafrazine may increase the hypotensive activities of Xipamide.Experimental
XylometazolineSafrazine may increase the hypotensive activities of Xylometazoline.Approved
ZimelidineSafrazine may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilSafrazine may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Safrazine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
PubChem Compound
34042
PubChem Substance
310265156
ChemSpider
31375
ChEMBL
CHEMBL3301845
Wikipedia
Safrazine
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.24 mg/mLALOGPS
logP1.51ALOGPS
logP1.69ChemAxon
logS-2ALOGPS
pKa (Strongest Basic)5.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area56.51 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.05 m3·mol-1ChemAxon
Polarizability23.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzodioxoles. These are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodioxoles
Sub Class
Not Available
Direct Parent
Benzodioxoles
Alternative Parents
Benzenoids / Oxacyclic compounds / Alkylhydrazines / Acetals / Hydrocarbon derivatives
Substituents
Benzodioxole / Benzenoid / Alkylhydrazine / Oxacycle / Acetal / Organic nitrogen compound / Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 22:19 / Updated on October 02, 2017 06:14